This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Casimiro, M. Articles by Albanese, C. Search for Related Content PubMed PubMed Citation Articles by Casimiro, M. Articles by Albanese, C.

ErbB-2 Induces the Cyclin D1 Gene in Prostate Epithelial Cells In vitro and In vivo

¹ Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania; ² Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia; ³ Keck School of Medicine, University of Southern California, Los Angeles, California; ⁴ Rutgers University, New Brunswick, New Jersey; ⁵ Ohio State University, Columbus, Ohio; ⁶ M. D. Anderson Cancer Center, University of Texas, Houston, Texas; and ⁷ McGill University Health Center, Montreal, Canada

Requests for reprints: Chris Albanese, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057. Phone: 202-687-3305; E-mail: albanese{at}georgetown.edu.

The receptor tyrosine kinase ErbB-2 plays an important role in the regulation of growth factor–induced signal transduction cascades in the epithelium, and ErbB-2 is frequently overexpressed in epithelial tumors. Our previous studies on clinical prostate cancer specimens indicated that ErbB-2 expression was increased in patients undergoing hormone ablation therapy. We had also shown that the critical cell cycle regulatory gene cyclin D1 and its promoter were targets of proliferative signaling in prostate cancer cell lines, and that cyclin D1 was required for ErbB-2–induced mammary tumorigenesis. In the current studies, we found that increased ErbB-2 membrane expression correlated with increased nuclear cyclin D1 staining in clinical prostate cancer specimens, and that expression of ErbB-2 was capable of inducing cell cycle progression in human prostate cancer cell lines. We further showed that ErbB-2 induced the cyclin D1 promoter in DU145 cells, and that small interfering RNA knockdown of cyclin D1 protein levels blocked a significant proportion of the heregulin-induced cell cycle progression in LNCaP cells. Probasin promoter–targeted expression of an activated ErbB-2 isoform induced cyclin D1 expression in the mouse prostate, commensurate with prostate intraepithelial neoplasia. Together, these in vitro and in vivo studies identify cyclin D1 as a critical downstream target of ErbB-2 in the prostate epithelium, both of which are possible therapeutic targets for cancer intervention. Furthermore, our novel mouse model provides a useful platform for ongoing in vivo investigations of ErbB-2 signaling in the prostate epithelium. [Cancer Res 2007;67(9):4364–72]

This article has been cited by other articles:

				O. C. Rodriguez, E. W. Lai, S. Vissapragada, C. Cromelin, M. Avetian, P. Salinas, H. Ramos, B. Kallakury, M. Casimiro, M. P. Lisanti, et al. A Reduction in Pten Tumor Suppressor Activity Promotes ErbB-2-Induced Mouse Prostate Adenocarcinoma Formation through the Activation of Signaling Cascades Downstream of PDK1 Am. J. Pathol., June 1, 2009; 174(6): 2051 - 2060. [Abstract] [Full Text] [PDF]

				M. Saleem, I. Murtaza, R. S. Tarapore, Y. Suh, V. M. Adhami, J. J. Johnson, I. A. Siddiqui, N. Khan, M. Asim, B. B. Hafeez, et al. Lupeol inhibits proliferation of human prostate cancer cells by targeting {beta}-catenin signaling Carcinogenesis, May 1, 2009; 30(5): 808 - 817. [Abstract] [Full Text] [PDF]

				L. J. Inge, S. A. Rajasekaran, D. Wolle, S. P. Barwe, S. Ryazantsev, C. M. Ewing, W. B. Isaacs, and A. K. Rajasekaran {alpha}-Catenin overrides Src-dependent activation of {beta}-catenin oncogenic signaling Mol. Cancer Ther., June 1, 2008; 7(6): 1386 - 1397. [Abstract] [Full Text] [PDF]